Cargando…

Current perspective on rituximab in rheumatic diseases

The steadily increasing knowledge regarding pathogenetic mechanisms in autoimmune rheumatic diseases has paved the way to different therapeutic approaches. In particular, the market entry of biologics has dramatically modified the natural history of rheumatic chronic inflammatory diseases with a mea...

Descripción completa

Detalles Bibliográficos
Autores principales: Schioppo, Tommaso, Ingegnoli, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633295/
https://www.ncbi.nlm.nih.gov/pubmed/29042750
http://dx.doi.org/10.2147/DDDT.S139248
_version_ 1783269865149169664
author Schioppo, Tommaso
Ingegnoli, Francesca
author_facet Schioppo, Tommaso
Ingegnoli, Francesca
author_sort Schioppo, Tommaso
collection PubMed
description The steadily increasing knowledge regarding pathogenetic mechanisms in autoimmune rheumatic diseases has paved the way to different therapeutic approaches. In particular, the market entry of biologics has dramatically modified the natural history of rheumatic chronic inflammatory diseases with a meaningful impact on patients’ quality of life. Among the wide spectrum of available biological treatments, rituximab (RTX), first used in the treatment of non-Hodgkin’s lymphoma, was later approved for rheumatoid arthritis and anti-neutrophil cytoplasmic antibodies-associated vasculitis. Nowadays, in rheumatology, RTX is also used with off-label indications in patients with systemic sclerosis, Sjögren’s syndrome and systemic lupus erythematosus. RTX is a monoclonal antibody directed to CD20 molecules expressed on the surfaces of pre-B and mature B lymphocytes. It acts by causing apoptosis of these cells with antibody- and complement-dependent cytotoxicity. As inflammatory responses to cell-associated immune complexes are key elements in the pathogenesis of several autoimmune rheumatic diseases, such an approach might be effective in these patients. In fact, RTX, by promoting the rapid and long-term depletion of circulating and lymphoid tissue-associated B cells, leads to a lower recruitment of these effector cells at sites of immune complex deposition, thus reducing inflammation and tissue damage. RTX is of the most interest to rheumatologists as it represents an important additional therapeutic approach. Thus, the advent in clinical practice of approved RTX biosimilars, such as CT-P10, may be of help in improving treatment access as well as in reducing costs.
format Online
Article
Text
id pubmed-5633295
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56332952017-10-17 Current perspective on rituximab in rheumatic diseases Schioppo, Tommaso Ingegnoli, Francesca Drug Des Devel Ther Review The steadily increasing knowledge regarding pathogenetic mechanisms in autoimmune rheumatic diseases has paved the way to different therapeutic approaches. In particular, the market entry of biologics has dramatically modified the natural history of rheumatic chronic inflammatory diseases with a meaningful impact on patients’ quality of life. Among the wide spectrum of available biological treatments, rituximab (RTX), first used in the treatment of non-Hodgkin’s lymphoma, was later approved for rheumatoid arthritis and anti-neutrophil cytoplasmic antibodies-associated vasculitis. Nowadays, in rheumatology, RTX is also used with off-label indications in patients with systemic sclerosis, Sjögren’s syndrome and systemic lupus erythematosus. RTX is a monoclonal antibody directed to CD20 molecules expressed on the surfaces of pre-B and mature B lymphocytes. It acts by causing apoptosis of these cells with antibody- and complement-dependent cytotoxicity. As inflammatory responses to cell-associated immune complexes are key elements in the pathogenesis of several autoimmune rheumatic diseases, such an approach might be effective in these patients. In fact, RTX, by promoting the rapid and long-term depletion of circulating and lymphoid tissue-associated B cells, leads to a lower recruitment of these effector cells at sites of immune complex deposition, thus reducing inflammation and tissue damage. RTX is of the most interest to rheumatologists as it represents an important additional therapeutic approach. Thus, the advent in clinical practice of approved RTX biosimilars, such as CT-P10, may be of help in improving treatment access as well as in reducing costs. Dove Medical Press 2017-10-03 /pmc/articles/PMC5633295/ /pubmed/29042750 http://dx.doi.org/10.2147/DDDT.S139248 Text en © 2017 Schioppo and Ingegnoli. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Schioppo, Tommaso
Ingegnoli, Francesca
Current perspective on rituximab in rheumatic diseases
title Current perspective on rituximab in rheumatic diseases
title_full Current perspective on rituximab in rheumatic diseases
title_fullStr Current perspective on rituximab in rheumatic diseases
title_full_unstemmed Current perspective on rituximab in rheumatic diseases
title_short Current perspective on rituximab in rheumatic diseases
title_sort current perspective on rituximab in rheumatic diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633295/
https://www.ncbi.nlm.nih.gov/pubmed/29042750
http://dx.doi.org/10.2147/DDDT.S139248
work_keys_str_mv AT schioppotommaso currentperspectiveonrituximabinrheumaticdiseases
AT ingegnolifrancesca currentperspectiveonrituximabinrheumaticdiseases